Inflammation Associated Articles & Analysis
17 news found
Asthma remains a complex and multifactorial disease, with airway hyperresponsiveness to methacholine being a hallmark feature. A recent study by Rojas-Ruiz et al (2025) utilizes SCIREQ’s innovative physioLens (ex vivo) and flexiVent (in vivo) platforms to shed light on the interplay between lung tissue compliance and methacholine response, offering new insights into the mechanisms ...
The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of bioresorbable stent that prevents the complications associated with metal stents. Severe peripheral vascular disease (PVD) is caused by the formation of blockages in arteries, ...
We look forward to providing safety and efficacy Phase 2 results in the first half of 2022 with BX005, which is designed to target Staphylococcus aureus, a bacteria associated with the exacerbation of inflammation in atopic dermatitis.” Poster Presentation Details: Poster Title: Development of a Bacteriophage Cocktail Targeting Staphylococcus aureus to ...
ByBiomX
The H-Guard priming solution could revolutionize kidney dialysis, it has the potential to significantly reduce inflammation and its associated complications. I am very excited to see the company progress and bring this product to ...
COVID-19 is associated with myocardial inflammation which may cause or exacerbate arrhythmias. ...
BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis. In this initial trial, BEN-2293 will be studied in adult patients ...
“Atopic dermatitis is not just a debilitating condition for millions of children, but is also a gateway condition associated with numerous chronic conditions that carry a lifelong physical, emotional and financial burden,” said David Kyle, Ph.D., Chairman of the Board and Chief Scientific Officer, Evolve BioSystems, Inc. ...
These important benefits were observed without increased safety risk associated with Hydrus surgery. No other MIGS device has presented outcome data in a pivotal trial beyond 2 years. ...
By targeting eotaxin and its downstream effects, AKST4290 may reduce the hallmark inflammation and neovascularization of AMD while also acting more broadly to reduce inflammation associated with many other age-related diseases. ...
“AKST4290 suppresses immune-mediated pathways and chronic inflammation and, if effective, could represent an important step forward in the treatment of Parkinson’s disease. ...
By targeting eotaxin and its downstream effects, AKST4290 may reduce the hallmark inflammation and neovascularization of AMD while also acting more broadly to reduce inflammation associated with many other age-related diseases. ...
The safety and effectiveness of the Hydrus® Microstent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, eyes with significant prior trauma, eyes with abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, eyes with ...
“So far there is no approved therapy for autoinflammatory diseases associated with high free IL-18 levels. As a result, there is a high unmet medical need among patients suffering from these severe and life-threatening conditions. ...
Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation. Topical AOTC is a Health Canada approved natural health product indicated for temporary relief of aches and pains of muscles and joints associated with simple ...
” This process led Naguib and Foss to look at the effects of an abnormal protein in the brain, amyloid, which builds up in Alzheimer’s patients and causes brain inflammation. Naguib and Foss think they have discovered a compound that will disrupt the inflammation associated with the buildup of the amyloid and thereby prevent or slow ...
Following damage, the TLRs interact with the tumor suppressor gene p53 to regulate the amount of inflammation. The NIEHS investigators also establish that the integration of p53 and inflammation only occurs in primates. ...
Following damage, the TLRs interact with the tumor suppressor gene p53 to regulate the amount of inflammation. The NIEHS investigators also establish that the integration of p53 and inflammation only occurs in primates. ...